Alicia Goodman
Personalreferent bei CERUS CORPORATION
Profil
Alicia Goodman is currently the Chief Human Resources Officer at Cerus Corp.
Prior to this, she was the Senior Vice President of Human Resources at Aimmune Therapeutics, Inc. from 2019 to 2023.
She also served as the Vice President of Human Resources at Novartis AG and the Senior VP, Chief People & Culture Officer at Berg LLC.
Ms. Goodman received her undergraduate degree from Michigan State University and her graduate degree from Central Michigan University.
Aktive Positionen von Alicia Goodman
| Unternehmen | Position | Beginn |
|---|---|---|
| CERUS CORPORATION | Personalreferent | 27.09.2023 |
Ehemalige bekannte Positionen von Alicia Goodman
| Unternehmen | Position | Ende |
|---|---|---|
| AIMMUNE THERAPEUTICS, INC. | Personalreferent | 01.02.2023 |
| NOVARTIS AG | Personalreferent | - |
Berg LLC
 Berg LLC Pharmaceuticals: MajorHealth Technology Berg LLC operates as a biopharmaceutical company, which focuses on taking a bold back to biology approach to therapeutic discovery using its Interrogative Biology platform. Its therapeutics include cancer metabolism and BPM 31510, chemotherapy induced alopecia and BPM 315453, neurology-discovery program, and metabolic disease-discovery program. The company was founded by Carl Edwin Berg, Mitch Gray, and Niven R. Narain in 2006 and is headquartered in Framingham, MA. | Personalreferent | - |
Ausbildung von Alicia Goodman
| Central Michigan University | Graduate Degree |
| Michigan State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NOVARTIS AG | Health Technology |
| CERUS CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Berg LLC
Berg LLC Pharmaceuticals: MajorHealth Technology Berg LLC operates as a biopharmaceutical company, which focuses on taking a bold back to biology approach to therapeutic discovery using its Interrogative Biology platform. Its therapeutics include cancer metabolism and BPM 31510, chemotherapy induced alopecia and BPM 315453, neurology-discovery program, and metabolic disease-discovery program. The company was founded by Carl Edwin Berg, Mitch Gray, and Niven R. Narain in 2006 and is headquartered in Framingham, MA. | Health Technology |
